carbamazepine
E850013
Carbamazepine is an anticonvulsant and mood-stabilizing drug commonly used to treat epilepsy, trigeminal neuralgia, and bipolar disorder.
Statements (73)
| Predicate | Object |
|---|---|
| instanceOf |
anticonvulsant drug
ⓘ
antiepileptic drug ⓘ dibenzazepine derivative ⓘ mood stabilizer ⓘ pharmaceutical drug ⓘ |
| hasAdverseEffect |
ataxia
ⓘ
dizziness ⓘ drowsiness ⓘ hyponatremia ⓘ leukopenia ⓘ nausea ⓘ vomiting ⓘ |
| hasATCCode |
N03AF01
ⓘ
N05AN01 ⓘ |
| hasBioavailability | 70–85% ⓘ |
| hasBlackBoxWarning |
aplastic anemia and agranulocytosis risk
ⓘ
serious dermatologic reactions ⓘ |
| hasCASNumber | 298-46-4 ⓘ |
| hasChemicalFormula | C15H12N2O ⓘ |
| hasCommonBrandName |
Carbatrol
GENERATED
ⓘ
Epitol GENERATED ⓘ Equetro GENERATED ⓘ Tegretol GENERATED ⓘ |
| hasDosageForm |
extended-release tablet
ⓘ
oral suspension ⓘ tablet ⓘ |
| hasDrugInteraction |
oral contraceptives
ⓘ
other antiepileptic drugs ⓘ warfarin NERFINISHED ⓘ |
| hasEliminationHalfLife |
approximately 12–17 hours (chronic use)
ⓘ
approximately 25–65 hours (single dose) ⓘ |
| hasIUPACName | 5H-dibenz[b,f]azepine-5-carboxamide ⓘ |
| hasLegalStatus | prescription-only medicine ⓘ |
| hasMechanismOfAction |
reduces neuronal excitability
ⓘ
voltage-gated sodium channel blocker ⓘ |
| hasMetabolism | hepatic ⓘ |
| hasMolarMass | 236.27 g/mol ⓘ |
| hasPharmacogenomicAssociation |
HLA-A*3101 allele
NERFINISHED
ⓘ
HLA-B*1502 allele NERFINISHED ⓘ |
| hasPregnancyRisk | teratogenic ⓘ |
| hasProteinBinding | 70–80% ⓘ |
| hasRouteOfAdministration |
oral
ⓘ
rectal ⓘ |
| hasSeriousAdverseEffect |
Stevens–Johnson syndrome
NERFINISHED
ⓘ
agranulocytosis ⓘ aplastic anemia ⓘ toxic epidermal necrolysis ⓘ |
| hasUNII | 33CM23913M ⓘ |
| induces |
CYP1A2
NERFINISHED
ⓘ
CYP2C19 NERFINISHED ⓘ CYP2C9 NERFINISHED ⓘ CYP3A4 NERFINISHED ⓘ UGT enzymes ⓘ |
| isContraindicatedIn |
patients with a history of hypersensitivity to tricyclic compounds
ⓘ
patients with bone marrow depression ⓘ |
| isContraindicatedWith | MAO inhibitors ⓘ |
| isExcretedBy |
bile
ⓘ
kidney ⓘ |
| isListedOn | World Health Organization Model List of Essential Medicines NERFINISHED ⓘ |
| isMetabolizedBy | CYP3A4 NERFINISHED ⓘ |
| mayCause | neural tube defects in fetus ⓘ |
| mayTreat |
neuropathic pain
ⓘ
schizoaffective disorder ⓘ |
| requiresGeneticTestingIn | many patients of Asian ancestry ⓘ |
| treats |
acute manic episodes
ⓘ
bipolar disorder ⓘ epilepsy ⓘ generalized tonic-clonic seizures ⓘ partial seizures ⓘ trigeminal neuralgia ⓘ |
| wasDevelopedBy | Janssen Pharmaceutica NERFINISHED ⓘ |
| wasFirstMarketedIn | 1960s ⓘ |
| wasFirstSynthesizedIn | 1953 ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.